Cargando…

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

BACKGROUND: SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone deacetylases. Preclinical evaluation of SB939 revealed a profile suggesting improved efficacy compared to other HDAC inhibitors. This phase I study was carried out to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048208/ https://www.ncbi.nlm.nih.gov/pubmed/21285985 http://dx.doi.org/10.1038/bjc.2011.13

Ejemplares similares

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
por: Novotny-Diermayr, V, et al.
Publicado: (2012)

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
por: Rauzan, Muhammad, et al.
Publicado: (2017)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
por: Witt, A E, et al.
Publicado: (2017)

Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
por: Kelly, R. D. W., et al.
Publicado: (2018)

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015)

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)

The Histone Deacetylase HDAC4 Regulates Long-Term Memory in Drosophila
por: Fitzsimons, Helen L., et al.
Publicado: (2013)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Bioactivity Studies of Hesperidin and XAV939
por: Fazary, Ahmed E., et al.
Publicado: (2021)

Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
por: Liu, Bin, et al.
Publicado: (2020)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs
por: Hanigan, Thomas W., et al.
Publicado: (2017)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Nuclear Receptor Corepressors are Required for the Histone Deacetylase Activity of HDAC3 In Vivo
por: You, Seo-Hee, et al.
Publicado: (2013)

In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs
por: Wang, Changning, et al.
Publicado: (2014)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
por: Boucherat, Olivier, et al.
Publicado: (2017)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice
por: Jia, Haiqun, et al.
Publicado: (2016)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer
por: Cui, Zhuhong, et al.
Publicado: (2018)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
por: Kim, Min Young, et al.
Publicado: (2020)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Male histone deacetylase 6 (HDAC6) knockout mice have enhanced ventilatory responses to hypoxic challenge
por: Getsy, Paulina M., et al.
Publicado: (2023)

Insights into the Recruitment of Class IIa Histone Deacetylases (HDACs) to the SMRT/NCoR Transcriptional Repression Complex
por: Hudson, Gregg M., et al.
Publicado: (2015)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
por: Garmpis, Nikolaos, et al.
Publicado: (2022)

A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors
por: Smith, Johanna A, et al.
Publicado: (2010)

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
por: Chen, E X, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e18hdk8rdqd74p1h47sgovpvp0